JP4685443B2 - 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン - Google Patents

悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン Download PDF

Info

Publication number
JP4685443B2
JP4685443B2 JP2004506847A JP2004506847A JP4685443B2 JP 4685443 B2 JP4685443 B2 JP 4685443B2 JP 2004506847 A JP2004506847 A JP 2004506847A JP 2004506847 A JP2004506847 A JP 2004506847A JP 4685443 B2 JP4685443 B2 JP 4685443B2
Authority
JP
Japan
Prior art keywords
lactoferrin
tumor
cancer
cells
rhlf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004506847A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533029A5 (ja
JP2005533029A (ja
Inventor
バラダカーリ、アトゥル
バースキー、リック
ペリクル、フレデリカ
ペトラック、カレル
ワン、イェンユン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of JP2005533029A publication Critical patent/JP2005533029A/ja
Publication of JP2005533029A5 publication Critical patent/JP2005533029A5/ja
Application granted granted Critical
Publication of JP4685443B2 publication Critical patent/JP4685443B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004506847A 2002-05-10 2003-05-09 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン Expired - Fee Related JP4685443B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37944202P 2002-05-10 2002-05-10
US37947402P 2002-05-10 2002-05-10
US37944102P 2002-05-10 2002-05-10
PCT/US2003/014789 WO2003099323A1 (en) 2002-05-10 2003-05-09 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010274944A Division JP5156084B2 (ja) 2002-05-10 2010-12-09 定着固形癌の治療におけるラクトフェリン

Publications (3)

Publication Number Publication Date
JP2005533029A JP2005533029A (ja) 2005-11-04
JP2005533029A5 JP2005533029A5 (ja) 2006-02-16
JP4685443B2 true JP4685443B2 (ja) 2011-05-18

Family

ID=29424524

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004506847A Expired - Fee Related JP4685443B2 (ja) 2002-05-10 2003-05-09 悪性新生物および他の過剰増殖性疾患の治療におけるラクトフェリン
JP2010274944A Expired - Fee Related JP5156084B2 (ja) 2002-05-10 2010-12-09 定着固形癌の治療におけるラクトフェリン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010274944A Expired - Fee Related JP5156084B2 (ja) 2002-05-10 2010-12-09 定着固形癌の治療におけるラクトフェリン

Country Status (11)

Country Link
US (5) US7901879B2 (enExample)
EP (2) EP1507554B1 (enExample)
JP (2) JP4685443B2 (enExample)
CN (2) CN100467060C (enExample)
AT (1) ATE519499T1 (enExample)
AU (2) AU2003273182B8 (enExample)
CA (1) CA2484656A1 (enExample)
CY (1) CY1111999T1 (enExample)
DK (1) DK1507554T3 (enExample)
PT (1) PT1507554E (enExample)
WO (2) WO2003099323A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399570B1 (en) 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
AU2003273182B8 (en) * 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US7238661B2 (en) * 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
AU2003270690B2 (en) * 2002-09-16 2009-07-30 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
CA2508912A1 (en) * 2002-12-06 2004-06-24 Agennix Incorporated Oral lactoferrin in the treatment of sepsis
WO2004052305A2 (en) 2002-12-10 2004-06-24 Agennix Incorporated Lactoferrin as an agent in the prevention of organ transplant rejection and graft-versus-host-disease
WO2004054608A2 (en) * 2002-12-12 2004-07-01 Agennix Incorporated Lactoferrin in the reduction of pain
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
GB0413954D0 (en) * 2004-06-22 2004-07-28 Altunkaya Ali Compositions for topical treatment
US7183381B2 (en) * 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
NZ555134A (en) * 2004-11-19 2010-07-30 Fonterra Co Operative Group Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
WO2007022537A2 (en) * 2005-08-19 2007-02-22 Agennix Incorporated Use of lactoferrin as a chemokine and a chemotactic modulator
ES2874482T3 (es) * 2006-03-03 2021-11-05 Oncosec Medical Inc Método y dispositivo para el tratamiento de los tumores residuales microscópicos que permanecen en los tejidos después de la resección quirúrgica
BRPI0713642A2 (pt) * 2006-06-14 2012-10-23 Nutricia Nv composição anti-inflamatória, e, uso de uma composição
RU2011115184A (ru) * 2008-09-19 2012-10-27 Нестек С.А. (Ch) Питательная поддержка для предупреждения или ослабления паралича костного мозга или нейтропении во время противораковой терапии
NZ594212A (en) * 2009-01-28 2013-01-25 Jean Paul Perraudin Method for production of lactoferrin
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP2015067560A (ja) * 2013-09-27 2015-04-13 国立大学法人広島大学 ラクトフェリンを含有する癌転移抑制剤
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9895410B2 (en) 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN106174462A (zh) * 2016-04-17 2016-12-07 马鞍山市志诚科技有限公司 一种防治血管瘤的营养配方纳米颗粒及制备加工方法
WO2018079701A1 (ja) * 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
CN111544579A (zh) * 2020-03-13 2020-08-18 中国农业科学院北京畜牧兽医研究所 一种抗癌症的药物组合物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6351337A (ja) * 1986-08-22 1988-03-04 Snow Brand Milk Prod Co Ltd 抗腫瘍剤
US4977137B1 (en) 1987-06-03 1994-06-28 Baylor College Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
IL94183A (en) * 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5198419A (en) * 1989-12-08 1993-03-30 Immuno Japan Inc. Formulated medicines for enhancing the efficacy of beta-lactam antibiotics in prophylaxis and treatment against infectious disease due to pathogenic bacteria
JPH06508371A (ja) 1991-06-21 1994-09-22 ユニバーシティー オブ シンシナティ 経口投与できる治療用タンパク質及びその製法
JP3184923B2 (ja) * 1992-01-08 2001-07-09 ビオ セレ ラボラトワール エス ア 抗リウマチ剤
ZA932568B (en) * 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5679807A (en) * 1995-01-30 1997-10-21 Hauser, Inc. Preparation of taxol and docetaxel through primary amines
JPH08217693A (ja) * 1995-02-17 1996-08-27 Yoshihisa Naito 新規医薬組成物
JP3888707B2 (ja) * 1996-01-22 2007-03-07 森永乳業株式会社 血管新生病治療剤
JP3496387B2 (ja) 1996-01-23 2004-02-09 花王株式会社 毛髪化粧料
US6111081A (en) 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
EP0920331A1 (en) * 1996-08-12 1999-06-09 A+ Science Invest AB Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
AU6307698A (en) 1997-02-03 1998-08-25 Pharming Bv Useful properties of human lactoferrin and variants thereof
AU747385C (en) 1997-04-10 2003-01-30 Agennix, Inc. Use of lactoferin in the treatment of allergen induced disorders
DE69914911T2 (de) * 1998-06-26 2004-12-09 Naamloze Vennootschap Nutricia Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
GB9818938D0 (en) * 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
JP2000229881A (ja) * 1999-02-10 2000-08-22 Morinaga Milk Ind Co Ltd 癌疾患の予後改善剤
RU2165769C1 (ru) 2000-07-13 2001-04-27 Якубовская Раиса Ивановна Антибактериальный, антиоксидантный, иммуномодулирующий и антиканцерогенный препарат и способ его применения
US20030096736A1 (en) * 2001-05-09 2003-05-22 Kruzel Marian L. Lactoferrin for age related disorders in humans
AU2003273182B8 (en) * 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US7238661B2 (en) * 2002-05-24 2007-07-03 Agennix, Inc. Oral lactoferrin in the treatment of respiratory disorders
AU2003270690B2 (en) * 2002-09-16 2009-07-30 Agennix Incorporated Lactoferrin compositions and methods of wound treatment
US8105615B2 (en) * 2003-06-06 2012-01-31 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
WO2005018542A2 (en) * 2003-07-10 2005-03-03 Agennix Incorporated Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
NZ555134A (en) 2004-11-19 2010-07-30 Fonterra Co Operative Group Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
JP2007233064A (ja) 2006-03-01 2007-09-13 Bitsign:Kk 表示システム及び表示器

Also Published As

Publication number Publication date
US20120276126A1 (en) 2012-11-01
CA2484656A1 (en) 2003-12-04
WO2003094952A1 (en) 2003-11-20
US7901879B2 (en) 2011-03-08
US8242079B2 (en) 2012-08-14
US20040009895A1 (en) 2004-01-15
US20040082504A1 (en) 2004-04-29
CN1668326A (zh) 2005-09-14
CN1668325A (zh) 2005-09-14
EP1507554A1 (en) 2005-02-23
DK1507554T3 (da) 2011-11-21
EP1507554B1 (en) 2011-08-10
HK1080722A1 (zh) 2006-05-04
JP2011079858A (ja) 2011-04-21
US20100137208A1 (en) 2010-06-03
HK1083203A1 (zh) 2006-06-30
WO2003099323A1 (en) 2003-12-04
JP2005533029A (ja) 2005-11-04
CY1111999T1 (el) 2015-11-04
JP5156084B2 (ja) 2013-03-06
CN100467059C (zh) 2009-03-11
AU2003273182B2 (en) 2009-04-23
EP2286827A1 (en) 2011-02-23
US20110076295A1 (en) 2011-03-31
ATE519499T1 (de) 2011-08-15
PT1507554E (pt) 2011-11-21
CN100467060C (zh) 2009-03-11
AU2003273182A1 (en) 2003-12-12
AU2003239393A1 (en) 2003-11-11
AU2003273182B8 (en) 2009-05-07
EP1507554A4 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
JP5156084B2 (ja) 定着固形癌の治療におけるラクトフェリン
US20110110983A1 (en) Lactoferrin as an adjuvant in cancer vaccines
CN104994866A (zh) 用空间构象改变的重组干扰素治疗肿瘤的方法
CN104688720A (zh) 绿原酸在制备治疗黑色素瘤的药物中的用途及治疗黑色素瘤的药物
TWI725947B (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
JP2023544310A (ja) プロバイオティクス成分の使用及びプロバイオティクス成分を含む医薬組成物
ES2368214T3 (es) Lactoferrina en el tratamiento de neoplasmas malignos y de otras enfermedades hiperproliferativas.
HK1080722B (en) The use of lactoferrin in the treatment of malignant neoplasms
HK1083203B (en) The use of intratumorally administered lactoferrin in the treatment of malignant neoplasms
KR102115468B1 (ko) 마이코박테리움 파라고르도네의 항암 면역치료법 용도
Yogeswaran et al. AN OVERVIEW OF CURCUMIN AS ADJUVANT IN CANCER VACCINES
CN115137831A (zh) 虾青素在制备抗血管生成药物增效剂中的应用以及一种药物组合物
Bowen Prevention and treatment of regimen-related mucosal toxicity
Yuasa et al. 316: A Novel Third Generation Bisphosphonate, Minodronic Acid, Augments the Interferon Alphabet a Mediated Inhibition of Renal cell Cancer cell Growth Both in Vitro and in vivo

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051222

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20081127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101209

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110201

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110210

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140218

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees